TABLE 4.
Rifapentine and main metabolite (25-desacetyl rifapentine) concentrations in ELF and ACs
| Drug | Mean ± SD concn (μg/ml) for the following group:
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 h (n = 5)
|
5 h (n = 5)
|
7 h (n = 5)
|
12 (n = 5)
|
24 (n = 5)
|
48 (n = 5)
|
|||||||
| AC | ELF | AC | ELF | AC | ELF | AC | ELF | AC | ELF | AC | ELF | |
| Rifapentine | 5.0 ± 4.2 | 3.2 ± 2.1 | 4.8 ± 2.4 | 3.7 ± 1.4a | 5.3 ± 2.5b | 2.3 ± 1.1c | 3.7 ± 1.4 | 3.0 ± 1.5 | 2.9 ± 1.3 | 2.0 ± 1.2 | 0.6 ± 1.0b | 0.7 ± 0.7a |
| 25-Desacetyl rifapentine | 0.9 ± 1.1c | 0.1 ± 0.1d | 0.6 ± 0.8 | 0.5 ± 0.5 | 0 | 0.5 ± 0.3 | 0.6 ± 0.6 | 1.8 ± 1.0d | 1.5 ± 1.0 | 0.8 ± 1.0 | 0.6 ± 1.0 | 0.2 ± 0.5 |
a
For ELF rifapentine concentration in 5-h group versus ELF rifapentine concentration in 48-h group, P < 0.05; all other comparisons were not significant (P > 0.05).
b
For AC rifapentine concentration in 7-h group versus AC rifapentine concentration in 48-h group, P < 0.05; all other comparisons were not significant (P > 0.05).
c
None of the differences in AC 25-desacetyl rifapentine concentrations were significant (P > 0.05).
d
For ELF 25-desacetyl rifapentine concentration in 12-h group versus 25-desacetyl rifapentine concentration in 4-h group, P < 0.05; all other comparisons were not significant.